Drug intelligence / Profile preview

OTTx peptide candidate (neuropathic pain)

Development stage: Preclinical
Lead developer: On Target Therapeutics
Modality: Peptides

Overview

OTTx peptide candidate (neuropathic pain) is a preclinical-stage, long-acting peptide modulator developed by On Target Therapeutics. The drug is designed to target an unspecified G protein-coupled receptor (GPCR) involved in pain signaling. By utilizing the company's platform for creating stable peptide modulators, the candidate aims to provide a durable therapeutic effect for the treatment of neuropathic pain. The program is currently in the preclinical phase, with the developer seeking industry partners for further clinical development and co-development into Phase I or Phase II trials.

Beyond the preview

Go deeper on OTTx peptide candidate (neuropathic pain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTTx peptide candidate (neuropathic pain).

Explore the full profile